idh mutations in aml treated with venetoclax
Published 3 years ago • 150 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
5:35
venetoclax plus hmas in idh-mutant aml
-
1:23
decitabine, venetoclax, and idh inhibitor in idh-mutated aml
-
2:08
the impact of idh mutations on the outcomes of patients with aml & inhibitors under investigation
-
1:14
the impact of idh mutations in mds & evaluating the role of idh inhibitors
-
2:57
targeting idh mutations for the treatment of aml
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
1:55
first-line venetoclax plus hma vs intensive chemotherapy in older adults with idh-mutated aml
-
0:48
asciminib for the treatment of cml
-
2:53
the prognostic impact of idh mutations and the role of idh inhibitors in mds
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:53
treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
-
1:45
ivosidenib with venetoclax in idh1-mutated hematological malignancies
-
3:57
the efficacy of flt3 and idh1/2 inhibitors in patients with aml previously treated with venetoclax
-
6:14
idh mutations in aml
-
6:52
ivosidenib and venetoclax /- azacitidine for idh1-mutated hematologic malignancies
-
3:11
genetic mutations as poor prognostic indicators of hct in venetoclax-treated aml
-
1:27
how do targeted treatments for idh1 and idh2 mutations work in acute myeloid leukemia (aml)?
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml